Navidea Biopharma (NAVB) Receives Orphan Designation for Lymphoseek in Head and Neck Cancers
Tweet Send to a Friend
Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) today announced that Lymphoseek® (technetium Tc 99m tilmanocept) Injection has been granted Orphan Drug Designation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
